The beginning of the new centenary finds the Vianex very high on the list of the National Pharmaceutical Industry, with its contribution to GDP rising to 1.3 billion euros according to the study of the group’s socioeconomic footprint for 2022.
Your 100 years of progress from the Giannakopoulos family In the field of medicine, VIANEX celebrated with the presence of representatives from the state and the business world. As the president and CEO of the VIANEX group said in his speech Dimitris Giannakopoulosat the beginning of the 2nd century, the group’s turnover is estimated at 500 million euros in 2024 and with operations in more than 100 countries, through strategic planning, vision and faith, it is in constant development, expansion, strengthening and continuity.
Giannakopoulos also referred to the group’s recent collaborations, such as strategic collaboration with genetics companies iDNA Genomics and iDNA Laboratories, who now join the group in the area of Precision Medicine and Genomic Analysis (DNA Testing) with the aim of personalized healthcare and also UBITEC in the area of Technology.
While the group’s vice president Konstantinos Panagoulias highlighted that the study of the group’s socioeconomic footprint for 2022 resulted in VIANEX’s contribution to GDP amounting to 1.3 billion euros and to Public Health through its pharmaceutical preparations it contributed to achieving 3,081 fewer hospitalizations and 5,551 more years of life.
The Minister of Health spoke at the event Adonis Georgiades, also representing the Prime Minister and highlighting that the greatest reward for a company is its recognition by the rest of the market. “It is important for Greece to have a VIANEX and I hope that in the future we will have more like it”, he noted. Adding that it is no coincidence that it is recognized by its 1,360 employees as the company with the best working conditions. At the same time, addressing representatives of the pharmaceutical industry, he said that he feels “higher” when he is abroad and is proud of the Greek pharmaceutical industry, which covers 10% of the total medicines market in Europe with its exports. Referring to the recovery of investment that affects almost the entire Greek pharmaceutical industry, he highlighted that it made it possible to invest 1.5 billion euros in the period 2020-2026. However, playing around and answering everyone’s questions about what’s wrong with that eventually recovery he said, “I don’t think it has a chance of being abolished in 1000 years,” causing both laughter from those present in the drug market and discontent with the safe establishment of mandatory reimbursements.
VIANEX social responsibility
As part of the event, two distinct social responsibility initiatives were announced that the VIANEX group will carry out in collaboration with Pavlos Giannakopoulos Foundation. Specifically, with the aim of contributing to the reduction of the low birth rate, as well as to a broader contribution to Greek society, they are providing financial support to families living permanently in rural areas of Greece with the birth of their third child. At the same time, in cooperation with the competent bodies, the group will distribute Greek flags to all first-year students in primary schools in the country during the 2024-2025 school year, thus reinforcing the sense of pride in the homeland.
Finally, it is important to mention that the president of the Association of Companies and Industries addressed a greeting Spyros Theodoropoulosthe president of the Association of Pharmaceutical Companies of Greece Olympios Papadimitriou and the president of the Panhellenic Pharmaceutical Industry Union,Theodore Tryphon.